PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Pharmacy, St. Michael\'s Hospital/Unity Health Toronto, Toronto, ON, Canada. beth.leung@utoronto.ca.\', \'Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada. beth.leung@utoronto.ca.\', \'Li Ka Shing Knowledge Institute, Toronto, ON, Canada. beth.leung@utoronto.ca.\', \'Ann Arbor Pharmacometrics Group, Ann Arbor, MI, USA.\', \'Department of Pharmacy, Mount Sinai Hospital, Toronto, ON, Canada.\', \'Institute of Medical Science, University of Toronto, Toronto, ON, Canada.\', \'Department of Pharmacy, North York General, Toronto, ON, Canada.\', \'Public Health Ontario, Toronto, ON, Canada.\', \'Department of Pharmacy, Northwestern Medicine, Chicago, IL, USA.\', \'Department of Pharmacy Practice, College of Pharmacy Downers Grove Campus, Midwestern University, Downers Grove, IL, USA.\', \'Pharmacometrics Center of Excellence, College of Pharmacy Downers Grove Campus, Midwestern University, Downers Grove, IL, USA.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1007/s40262-021-01092-0
?:hasPublicationType
?:journal
  • Clinical pharmacokinetics
is ?:pmid of
?:pmid
?:pmid
  • 34894345
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.482
?:rankingScore_hIndex
  • 146
?:title
  • Pharmacokinetic/Pharmacodynamic Considerations of Alternate Dosing Strategies of Tocilizumab in COVID-19.
?:type
?:year
  • 2022

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34894345>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34894345>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all